AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12898456
Drug: Alanine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alanine (1.5 mg. kg(‐1). min(‐1))
Trial: 3904885
Drug: Sulpiride (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (2000 mg/day, range 800-3200)
Trial: 3904885
Drug: Haloperidol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (12 mg/day, range 6-24)
Trial: 30797750
Drug: Levothyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine treatment for patients with thyroid-stimulating hormone values of more than 10 mIU/L
Trial: 30797750
Drug: Initiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of therapy for abnormal thyroid function
Trial: 31659776
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care (PC)
Trial: 26882833
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg of 5% ketamine)
Trial: 26882833
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg of 2% lidocaine)
Trial: 23093664
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (0.3 units · kg(‐1))
Trial: 23093664
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (0.6 units · kg(‐1))
Trial: 23093664
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (1.2 units · kg(‐1))
Trial: 19969374
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus atomoxetine (40‐120 mg/d)
Trial: 9660375
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of oral d‐fenfluramine (d‐FEN)
Trial: 7640447
Drug: Peritoneal lavage
RxNorm normalized name: Peritoneal Lavage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritoneal lavage with intravenous antibiotic therapy (aminoglycoside and cephem)
Trial: 7640447
Drug: Silicon tube
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicon tube drainage with the same systemic antibiotic therapy
Trial: 2751138
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg tetracaine with 0.2 mg epinephrine
Trial: 2751138
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg tetracaine alone
Trial: 2751138
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg tetracaine
Trial: 30538075
Drug: Telmisartan co-administration
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan co-administration
Trial: 27080379
Drug: Subarachnoid morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subarachnoid morphine (100μg)
Trial: 25052334
Drug: 21 mg
RxNorm normalized name: aspirin 421 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 mg nicotine patches for four weeks before quitting, whilst smoking as normal
Trial: 25052334
Drug: Not using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not using nicotine patches
Trial: 19726362
Drug: PA‐MSHA treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA‐MSHA treatment in addition to neoadjuvant chemotherapy
Trial: 19726362
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with neoadjuvant chemotherapy
Trial: 9893549
Drug: Sufentanil 2
RxNorm normalized name: SUFentanil 250 MCG in 5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 2 micrograms.ml‐1
Trial: 8179658
Drug: Nicotine 2
RxNorm normalized name: nicotine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 2 mg chewing gum
Trial: 8179658
Drug: Nicotine 4
RxNorm normalized name: nicotine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 4 mg chewing gum
Trial: 8179658
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy (gum and patch)
Trial: 2636484
Drug: Ultraviolet light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultraviolet light treatment of 50 ml venous blood
Trial: 8436158
Drug: Allomaron (allopurinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allomaron (allopurinol 100 mg plus benzbromarone 20 mg)
Trial: 8436158
Drug: Zyloprim (allopurinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zyloprim (allopurinol 100 mg)
Trial: 749193
Drug: Concurrent hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent hormonal therapy with combination chemotherapy
Trial: 749193
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy alone (control)
Trial: 749193
Drug: Chemotherapy programs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy programs (further random allocation)
Trial: 30818837
Drug: Internet-delivered cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive-behavioral therapy (ICBT)
Trial: 22686551
Drug: Face-to-face cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face cognitive-behavioral therapy (CBT)
Trial: 31774494
Drug: Training models
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training models for implementing evidence-based psychological treatment
Trial: 19632949
Drug: S-1 combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 combined with platinum compounds, irinotecan, and gemcitabine
Trial: 11906552
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant concurrent chemoradiotherapy (PCCRT)
Trial: 11906552
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy (PCT)
Trial: 11588535
Drug: Amlodipine (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5-10 mg, once daily)
Trial: 8031705
Drug: Enalapril (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10-40 mg, once daily)
Trial: 2590930
Drug: 7F catheter
RxNorm normalized name: pneumococcal capsular polysaccharide type 7F vaccine
DrugBank: Streptococcus pneumoniae type 7f capsular polysaccharide antigen (DB10325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7F catheter (hand injection)
Trial: 2590930
Drug: 5F catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5F catheter (hand injection)
Trial: 2590930
Drug: 5F catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5F catheter (power injection)
Trial: 5090759
Drug: Dermatological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermatological treatment plus psychiatric treatment (limited to four months)
Trial: 5090759
Drug: Dermatological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermatological treatment only
Trial: 28974124
Drug: Low-dose Dhaka
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Dhaka regime
Trial: 28974124
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose only regime
Trial: 22381714
Drug: Avagacestat (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avagacestat (0.3 to 800 mg)
Trial: 20299490
Drug: Triple stimulus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple stimulus (GHRP-2/GHRH/l-arginine)
Trial: 16334715
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10-day decrescendo therapy of methadone only)
Trial: 12921571
Drug: Combined chemoradiotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemoradiotherapy (Group A) - chemotherapy with 5‐fluorouracil and cisplatin for 2 cycles and radiotherapy of DT36 Gy/12 f/17 d followed by surgery
Trial: 11234740
Drug: VAQTA (hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAQTA (hepatitis A vaccine)
Trial: 11234740
Drug: HAVRIX (hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAVRIX (hepatitis A vaccine)
Trial: 24867312
Drug: Vehicle of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of latanoprost or physiological buffered saline solution (group 5 and 6)
Trial: 19016201
Drug: Intracameral cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracameral cefuroxime 1 mg in 0.1 mL isotonic NaCl solution
Trial: 16261220
Drug: Bicyclol 150
RxNorm normalized name: alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
DrugBank: Biperiden (DB00810)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicyclol 150 mg daily
Trial: 16261220
Drug: Bicyclol 75
RxNorm normalized name: alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
DrugBank: Biperiden (DB00810)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicyclol 75 mg daily
Trial: 12021520
Drug: Me‐Cbl 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Me‐Cbl 500 microg twice/week plus FA 10 mg/day
Trial: 12021520
Drug: FA 10
RxNorm normalized name: IDHIFA 100mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FA 10 mg/day alone
Trial: 12021520
Drug: Me‐Cbl 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Me‐Cbl 500 microg twice/week alone (Control Group D)
Trial: 1835324
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (54 micrograms after the first isoetharine treatment and 36 micrograms after the second and fourth treatments)
Trial: 1835324
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of nebulized isoetharine (0.5 mL of a 1% solution diluted to 2.0 mL with normal saline every hour)
Trial: 31113987
Drug: esaxerenone 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esaxerenone 1.25 mg/day
Trial: 31113987
Drug: esaxerenone 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esaxerenone 2.5 mg/day
Trial: 31113987
Drug: esaxerenone 5
RxNorm normalized name: Esaxerenone
DrugBank: Esaxerenone (DB15207)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: esaxerenone 5 mg/day
Trial: 31113987
Drug: eplerenone (50–100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eplerenone (50–100 mg/day)
Trial: 26514931
Drug: Amoxicillin 100mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 100mg/kg/day + 0.9% NSI
Trial: 26514931
Drug: Amoxicillin +
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin + 0.9% NSI
Trial: 25073939
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity ambulatory rehabilitation programmes (≥ 3 × 1‐h weekly sessions for approximately 10 weeks)
Trial: 25073939
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care programmes (≤ 2 × 1‐h weekly sessions)
Trial: 21084399
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (25-75 mg daily)
Trial: 17556785
Drug: Combination training
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination training (CT)
Trial: 15191514
Drug: Lansoprazole, clarithromycin
RxNorm normalized name: lansoprazole, clarithromycin and tinidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole, clarithromycin and tinidazole twice‐daily
Trial: 15191514
Drug: Lansoprazole, clarithromycin
RxNorm normalized name: lansoprazole, clarithromycin and tinidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole, clarithromycin and tinidazole once‐daily
Trial: 15191514
Drug: Placebo, clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, clarithromycin and tinidazole once‐daily
Trial: 15191514
Drug: Lansoprazole, clarithromycin
RxNorm normalized name: lansoprazole, clarithromycin and tinidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole, clarithromycin and tinidazole (both dosing regimens)
Trial: 11753827
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of secondary prophylaxis against cytomegalovirus (CMV)
Trial: 9834046
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg 4 times a day) for 10 days with concomitant clarithromycin (500 mg twice a day) from days 6 through 10
Trial: 9834046
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg twice a day) for 10 days combined with cisapride (10 mg 4 times a day) from days 6 through 10
Trial: 9834046
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg 4 times a day)
Trial: 24434382
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg twice a day)
Trial: 9706623
Drug: Vigabatrin 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin 150 mg/kg/day
Trial: 9706623
Drug: Vigabatrin 65-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin 65-75 mg/kg/day
Trial: 6703348
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 5 mg
Trial: 6703348
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 7.5 mg
Trial: 6859570
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine 7.5 mg
Trial: 26206451
Drug: Vaginal hysterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal hysterectomy with suspension of the uterosacral ligaments
Trial: 22537824
Drug: Smoking and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking and SE alleles combination
Trial: 20167988
Drug: Pre-emptive therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive therapy with valganciclovir (n=36)
Trial: 15858814
Drug: Optimized pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized pharmacological treatment (n=8)
Trial: 9147710
Drug: Egifilin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egifilin 200 mg retard tablet
Trial: 9147710
Drug: Egifilin 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egifilin 400 mg retard tablet
Trial: 3555852
Drug: Physostigmine and
RxNorm normalized name: Physostigmine and pilocarpine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine and lecithin combination
Trial: 20972285
Drug: RUTF (locally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RUTF (locally produced energy-dense supplement)
Trial: 18333868
Drug: Maraviroc 900
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc 900 mg
Trial: 18333868
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg (active comparator)
Trial: 18333868
Drug: Maraviroc (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc (all doses)
Trial: 18333868
Drug: Maraviroc (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc (up to 2363 ng ml(‐1))
Trial: 8554016
Drug: Reperfusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reperfusion therapy (intravenous thrombolytic agents or urgent percutaneous transluminal coronary angioplasty)
Trial: 1320913
Drug: Metoclopramide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (3 mg/kg) plus dexamethasone (12 mg)
Trial: 1320913
Drug: Chlorpromazine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (up to 200 mg/24 h) plus dexamethasone (12 mg)
Trial: 30391914
Drug: Continuous infusions
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusions of vancomycin (CIV)
Trial: 25156622
Drug: Alemtuzumab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alemtuzumab (30 mg intraoperatively)
Trial: 25156622
Drug: Rabbit anti-thymocyte
RxNorm normalized name: Rabbit anti-thymocyte immunoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabbit anti-thymocyte globulin (multiple doses starting intraoperatively)
Trial: 12097201
Drug: Radioiodine and
RxNorm normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine and lithium group (Li group) - lithium carbonate, 300 mg three times a day for 3 weeks starting on the day of radioiodine administration
Trial: 9858319
Drug: AVONEX (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVONEX (6 MIU single i.m. dose)
Trial: 22503722
Drug: Ca-group: 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca-group: 500 mg/d calcium
Trial: 22503722
Drug: Ca+MZ-group: 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca+MZ-group: 500 mg/d calcium + multivitamin tablet containing 15 mg/d zinc
Trial: 22503722
Drug: C-group: multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-group: multivitamin tablet without any minerals
Trial: 8618250
Drug: Multiple-dose activated
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose activated charcoal (six doses) and two doses of sorbitol over 24 hours
Trial: 6626409
Drug: Premedication with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication with diazepam 5 mg rectally and atropine 0.3‐0.4 mg sublingually (Group A)
Trial: 6289856
Drug: Rectal combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal combination of diazepam 0.5 mg kg‐1, morphine 0.15 mg kg‐1 and hyoscine 0.01 mg kg‐1 (Group B)
Trial: 26879200
Drug: Odanacatib (ODN)
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib (ODN) 50 mg weekly for up to 8 years
Trial: 26879200
Drug: Odanacatib (ODN)
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib (ODN) 50 mg weekly for up to 8 years with vitamin D3 (5600 IU) and calcium supplementation
Trial: 17846812
Drug: Methylphenidate Spheroidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate Spheroidal Oral Drug Absorption System (MPH-SODAS)
Trial: 10390392
Drug: Aerosolized uridine-5'-triphosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized uridine-5'-triphosphate (UTP) 5 mg/ml, 3.5 ml
Trial: 10390392
Drug: Vehicle (0.12%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (0.12% saline, 3.5 ml)
Trial: 9071082
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (2.5 mg in 3 ml)
Trial: 9071082
Drug: Nebulized metaproterenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized metaproterenol (15 mg in 3 ml)
Trial: 9071082
Drug: Nebulized saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized saline 3 ml (control group)
Trial: 1864451
Drug: 0.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/day Imedeen for 90 days
Trial: 6401426
Drug: Intranasal nitroglycerine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal nitroglycerine (NTG) administered 1 min before induction of anaesthesia
Trial: 30286760
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BJ) 70 ml (6.5 mmol NO3‐)
Trial: 26712474
Drug: Unscheduled health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unscheduled health care visits for asthma or use of oral corticosteroids in the previous year
Trial: 26712474
Drug: Pre- and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre- and post-bronchodilator ratios of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC)
Trial: 21966995
Drug: Fesoterodine 4
RxNorm normalized name: fesoterodine 4 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 mg (with optional dose escalation to 8 mg at week 4)
Trial: 20300709
Drug: Prevention programs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prevention programs and interventions in the field of drug abuse
Trial: 17950801
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg dabigatran plus aspirin
Trial: 17950801
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg dabigatran
Trial: 17950801
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dabigatran
Trial: 17950801
Drug: Dabigatran (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (50 mg, 150 mg, 300 mg)
Trial: 12089124
Drug: Metered Dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered Dose Inhaler (MDI) plus spacer (400 microg, 4 puffs)